Transcription factor decoy oligonucleotides modified with locked nucleic acids: An in vitro study to reconcile biostability with binding affinity

Nucleic Acids Research

Volumn 32, Issue 6, 2004, Pages 1874-1885

  Crinelli, Rita ^c   Bianchi, Marzia ^c   Gentilini, Lucia ^c   Palma, Linda ^c   Sørensen, Mads D ^a   Bryld, Torsten ^a   Babu, Ravindra B ^a   Arar, Khalil ^b   Wengel, Jesper ^a   Magnani, Mauro ^c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Proligo   (France)

^c UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEIC ACID; NUCLEIC ACID BASE; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR;

ARTICLE; BINDING AFFINITY; CONFORMATION; CONSENSUS SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR STABILITY; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

INSERTION SEQUENCES;

EID: 3042651091     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkh503     Document Type: Article

References (47)

1. Latchman,D.S. (1997) How can we use our growing understanding of gene transcription to discover effective new medicine? Curr. Opin. Biotechnol., 8, 713-717.
2. Latchman,D.S. (1997) Transcription factors: an overview. Int. J. Biochem. Cell Biol., 29, 1305-1312.
3. Johnson,W. and Jameson,J.L. (1998) Transcriptional control of gene expression. In Jameson,J.L. (ed.), Principles of Molecular Medicine. Humana Press, Totowa, NJ.
4. Latchman,D.S. (2000) Transcription factors as potential targets for therapeutic drugs. Curr. Pharm. Biotechnol., 1, 57-61.
5. Emery,J.G., Olhlstein,E.H. and Jaye,M. (2001) Therapeutic modulation of transcription factor activity. Trends Pharmacol. Sci., 22, 233-240.
6. Darnell,J.E.,Jr (2002) Transcription factors as targets for cancer therapy. Nature Rev. Cancer, 2, 740-749.
7. Papavassiliou,A.G. (1998) Transcription-factor-modulating agents: precision and selectivity in drug design. Mol. Med. Today, 4, 358-366.
8. Morishita,R., Higaki,J., Tomita,N. and Ogihara,T. (1998) Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ. Res., 82, 1023-1028.
9. Mann,M.J. and Dzau,V.J. (2000) Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Invest., 106, 1071-1075.
10. Tomita,N., Morishita,R., Tomita,T. and Ogihara,T. (2002) Potential therapeutic applications of decoy oligonucleotides. Curr. Opin. Mol. Ther., 4, 166-170.
11. Nakamura,H., Morishita,R. and Kaneda,Y. (2002) Molecular therapy via transcriptional regulation with double-stranded oligodeoxynucleotides as decoys. In Vivo, 16, 45-48.
12. Dzau,V.J. (2002) Transcription factor decoy. Circ. Res., 90, 1234-1236.
13. Tomita,N., Azuma,H., Kaneda,Y., Ogihara,T. and Morishita,R. (2003) Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular disease. Curr. Drug Targets, 4, 339-346.
14. Mann,M., Whittemore,A., Donaldson,M.C., Pollack,M.D., Orav,J. and Dzau,V.J. (1999) Ex vivo gene therapy of vascular bypass graft with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet, 354, 1493-1498.
15. Chu,B.C.F. and Orgel,L.E. (1992) The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res., 20, 5857-5858.
16. Bielinska,A., Shivdasani,R.A., Zhang,L. and Nabel,G.J. (1990) Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science, 250, 997-1000.
17. Mischiati,C., Borgatti,M., Bianchi,N., Rutigliano,C., Tomassetti,M., Feriotto,G. and Gambari,R. (1999) Interaction of the human NF-kB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kB binding sites of the human immunodeficiency virus type 1 promoter. J. Biol. Chem., 274, 33114-33122.
18. Brown,D.A., Kang,S.-H., Gryaznov,S.M., DeDionisio,L., Heidenreich,O., Sullivan,S., Xu,X. and Nerenberg,M.I. (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem., 269, 26801-26805.
19. Romanelli,A., Pedone,C., Saviano,M., Bianchi,N., Borgatti,M., Mischiati,C. and Gambari,R. (2001) Molecular interactions with nuclear factor-kB (NF-kB) transcription factors of PNA-DNA chimera mimicking NF-kB binding sites. Eur. J. Biochem., 268, 6066-6075.
20. Borgatti,M., Lampronti,I., Romanelli,A., Pedone,C., Saviano,M., Bianchi,N., Mischiati,C. and Gambari,R. (2003) Transcription factor decoy molecule based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J. Biol. Chem., 278, 7500-7509.
21. Crinelli,R., Bianchi,M., Gentilini,L. and Magnani,M. (2002) Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res., 30, 2435-2443.
22. Singh,S.K., Nielsen,P., Koshkin,A. and Wengel,J. (1998) LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem. Commun., 455-456.
23. Braasch,D.A. and Corey,D.R. (2000) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol., 55, 1-7.
24. Petersen,M. and Wengel,J. (2003) LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol., 21, 74-81.
25. Koshkin,A.A., Singh,S.K., Nielsen,P., Rajwanshi,V.K., Kumar,R., Meldgaard,M., Olsen,C.E. and Wengel,J. (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation and unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630.
26. Sørensen,M.D., Kvænø,L., Bryld,T., Hå kansson,A.E., Verbeure,B., Gaubert,G., Herdewijn,P. and Wengel,J. (2002) α-L-Ribo-configured locked nucleic acid (α-L-LNA): synthesis and properties. J. Am. Chem. Soc., 124, 2164-2176.
27. LGC :d(GCAGAAGCAG) duplex containing four locked nucleotides. Bioconjugate Chem., 11, 228-238.
28. Petersen,M., Nielsen,C.B., Nielsen,K.E., Jensen,G.A., Bondensgaard,K., Singh,S.K., Rajwanshi,V.K., Koshkin,A.A., Dahl,B.M., Wengel,J. and Jacobsen,J.P. (2000) The conformations of locked nucleic acids (LNA). J. Mol. Recognit., 13, 44-53.
29. Berkowitz,B., Huang,D.B., Chen-Park,F.E., Sigler,P.B. and Ghosh,G. (2002) The X-ray crystal structure of the NF-kB p50·p65 heterodimer bound to the interferon β-kB site. J. Biol. Chem., 277, 24694-24700.
30. Escalante,C.R., Shen,L., Thanos,D. and Aggarwall,A.K. (2002) Structure of the NF-kB p50/p65 heterodimer bound to the PRDII DNA element from the interferon-β promoter. Structure, 10, 383-391.
31. Grünweller,A., Wyszko,E., Bieber,B., Jahnel,R., Erdmann,V.A. and Kurreck,J. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′ -O-methyl RNA, phosphorothioate and small interfering RNA. Nucleic Acids Res., 31, 3185-3193.
32. Thanos.D. and Maniatis,T. (1992) The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-β gene. Cell, 71, 777-789.
33. Falvo,J.V., Thanos,D. and Maniatis,T. (1995) Reversal of intrinsic DNA bends in the IFNβ gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell, 83, 1101-1111.
34. Wengel,J., Petersen,M., Nielsen,K.E., Jensen,G.A., Hakansson,A.E., Kumar,R., Sorensen,M.D., Rajwanshi,V.K., Bryld,T. and Jacobsen,J.P. (2001) LNA (locked nucleic acid) and the diastereoisomeric alpha-L-LNA: conformational tuning and high affinity of DNA/RNA targets. Nucleosides Nucleotides Nucleic Acids, 20, 389-396.
35. Nielsen,K.M., Petersen,M., Håkansson,A.E., Wengel,J. and Jacobsen,J.P. (2002) α-L-LNA (α-L-ribo-configured locked nucleic acid) recognition of DNA: an NMR spectroscopic study. Eur. J. Chem., 8, 3001-3009.
36. Crooke,S.T. (2002) Progress in antisense technology: the end of the beginning. Methods Enzymol., 313, 3-45.
37. Boye,S.M., Pradhan,A.A. and Clarke,P.B. (2002) Evidence for sequence-dependent and reversible non-specific effects of PS-capped antisense treatment after intracerebral administration. Antisense Nucleic Acid Drug Dev., 12, 95-102.
38. 3H-labeled oligonucleotides. II. 3′,5′ -blocked oligonucleotides. Mol. Pharmacol., 47, 636-646.
39. Uhlmann,E., Peyman,A., Ryte,A., Schmidt,A. and Buddecke,E. (2000) Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol., 313, 268-284.
40. Hosoya,T., Takeuchi,H., Kanesaka,Y., Yamakawa,H., Miyano-Kurosaki,N., Takai,K., Yamamoto,N. and Takaku,H. (1999) Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett., 461, 136-140.
41. Wahlestedt,C., Salmi,P., Good,L., Kela,J., Johnsson,T., Hökfelt,T., Broberger,C., Porreca,F., Lai,J., Ren,K., Ossipov,M., Koshkin,A., Jakobsen,N., Skouv,J., Oerum,H., Jacobsen,M.H. and Wengel,J. (2000) Potent and non-toxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA, 97, 5633-5638.
42. Borgatti,M., Romanelli,A., Saviano,M., Pedone,C., Lampronti,I., Breda,L., Nastruzzi,C., Bianchi,N., Mischiati,C. and Gambari,R. (2003) Resistance of decoy PNA-DNA chimera to enzymatic degradation in cellular extracts and serum. Oncol. Res., 13, 279-287.
43. Saviano,M., Romanelli,A., Bucci,E., Pedone,C., Mischiati,C., Bianchi,N., Feriotto,G., Borgatti,M. and Gambari,R. (2000) Computational procedures to explain the different biological activity of DNA/DNA, DNA/PNA, PNA/PNA hybrid molecules mimicking NF-kB binding sites. J. Biomol. Struct. Dyn., 18, 353-362.
44. Koudelka,G.V., Harrison,S.C. and Ptashne,M. (1987) Effect of non-contacted bases on the affinity of 434 operator for 434 repressor and Cro. Nature, 326, 886-888.
45. Chen,F.E., Huang,D.-B., Chen,Y.-Q. and Ghosh,G. (1998) Crystal structure of p50-p65 heterodimer of transcription factor NF-kB bound to DNA. Nature, 391, 410-413.
46. Zabel,U., Schreck,R. and Bauerle,P. (1991) DNA binding of purified transcription factor NF-kB. J. Biol. Chem., 266, 252-260.
47. Magnani,M., Rossi,L., Fraternale,A., Bianchi,M., Antonelli,A., Crinelli,R. and Chiarantini,L. (2002) Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther., 9, 749-751.